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LETTERS TO THE EDITORBIOPROSTHETIC DURABILITY
ASSESSMENT: IMPORTANCE
OF COMPLETE DATA
To the Editor:
Myken and Bech-Hansen1 reported
a 20-year experience with the Biocor
valve (St Jude Medical, Inc, St Paul,
Minn). This study consisted of 1518
aortic valve replacements and 194 mi-
tral valve replacements (MVRs). The
predominant area of interest in the re-
port has been the durability of the
prosthesis in the mitral position. The
article reported on structural valve de-
terioration (SVD) as determined by
explant reoperation. The alternative
method of retrospective reporting is
to combine SVD by explant reopera-
tion and with SVD by clinical (echo-
cardiographic) evaluation. Myken
and Bech-Hansen1 reported echocar-
diographic performance but did not
include echocardiographic evaluation
in their durability analysis. Only
Kaplan–Meier actuarial data analysis
was reported, because their objective
was to report on prosthesis perfor-
mance and not performance in
a specific population subset (actual
cumulative incidence).
Myken and Bech-Hansen1 reported
promising results with respect to
MVR actuarial freedom from explant
reoperation for SVD. For patients
older than 65 years, the 20-year actu-
arial freedom from reoperation for
SVD in MVR was 88.0%. Two previ-
ous reports on MVR freedom from
reoperative SVD have illustrated sim-
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MVR populations with mean ages
of 48 and 49 years.2,3 Pomerantzeff
and colleagues3 in 2006 reported
favorable actuarial freedoms from
reoperation for SVD for MVR at
15 years of 88.7% for patients 51 to
60 years old and 84% for patients
61 to 80 years old. Kirali and col-
leagues2 reported in 2001 MVR actu-
arial freedom from reoperation for
SVD of 76.8% at 13 years. An im-
portant aspect of the latter publica-
tion is that the freedom from SVD
for all clinically documented cases
was 64.8% at 13 years (39 cases of
overall SVD vs 16 reoperative cases).
The distinctions in reporting of SVD
for MVR by the different definitions
are illustrated by Kirali and col-
leagues.2
Myken and Bech-Hansen1 reported
that for patients older than 65 years
undergoing aortic valve replacement
the 20-year actuarial freedom from re-
operation for SVD was 92.1%. In
2008, Eichinger and coauthors,4 in
a separate 20-year publication on the
Biocor prosthesis, reported actuarial
freedom from reoperation for SVD at
15 years of 90.6% for aortic valve re-
placement in a cohort of 455 patients
(mean age, 72.5  9 years). The actu-
arial freedom at 15 years for overall
SVD was 88.4%. Sixteen of 23 pa-
tients with SVD came to reoperation.
The actuarial freedom at 20 years
from reoperation for SVD was
86.5%. The distinctions in reporting
of SVD for aortic valve replacement
by the different definitions are illus-
trated by Eichinger and colleagues.4
The comparison of SVDs from var-
ious studies must always consider how
SVD is reported, either on the basis of
explant reoperation or on the basis of
a combination of explant reoperation
and clinical parameters. The currently
approved next generation of the Bio-
cor porcine bioprosthesis, the Epic
porcine bioprosthesis, needs durabil-
ity assessment, preferably combining
both methods of reporting SVD, by re-
operation explant and by reoperationardiovascular Surgery c February 2011explant combined with clinical (echo-
cardiographic) evaluation.
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We thank Drs Suyker and Leicher
for their comments1 regarding our
article reporting 20-year experience
of 1712 patients with the Biocor
(St Jude Medical, Inc, Minneapolis,
Minn) porcine bioprosthesis2 and
would like to respond. We agree that
one would wish for longer mean
follow-up; however, our study does
not differ significantly from other
20-year studies (Table 1).3-8 This
only reflects the increasing numbers
of bioprostheses inserted during this
period, a trend for the entire Western
world.
Suyker and Leicher1 are further
concerned that reporting actuarial
freedom from reoperation for struc-
tural valve deterioration (SVD) rather
than all SVD may underestimate
the impact of SVD. The difficulty is
that there is no specific definition
of SVD. All bioprostheses are gradu-
ally degenerating, and which valves
should categorize as affected by
SVD? Even if we had a consensus def-
inition, there is difficulty in obtaining
TABLE 1. Sample of long-term published studies
Valve type Reference
Mean
follow-up (y)
Maximum
follow-up (y) Determination of SVD
Biocor Myken and
Bech-Hansen2
6.0 aortic,
6.2 mitral
20 Reoperation for SVD
Mitroflow Yankah et al3 4.1 21 Reoperation for SVD
PERIMOUNT Biglioli et al4 6 18 Prosthesis replacement for SVD
PERIMOUNT Aupart et al5 5.5 18 Echocardiography indicated
by mean gradient>40 mm Hg
Carpentier-Edwards
S.A.V. porcine valve
Jamieson et al6 7.8 20 Reoperation and pathology reports from autopsy, or
echocardiography in patients with reduced functional class
Hancock II Borger et al7 7.4 (0–21) 20 Clinically relevant stenosis or regurgitation per
echocardiographic documentation or reoperation
PERIMOUNT Edwards
LifeSciences8
9 20 Explant for SVD
SVD, Structural valve deterioration.
Letters to the Editorechocardiograms for all patients
(because of old age and various other
reasons). Studies that report freedom
from all SVD generally have very
few patients reported with SVD who
do not undergo reoperation. It thus is
most unlikely that their numbers truly
reflect all SVD. In our opinion, it is
more fair to report SVD leading to re-
operation, because it is an objective
measurement. Suyker and Leicher1
have noted the uneven age distribution
with time, with older mean age in the
last decade than in the first. This re-
flects a trend in cardiovascular surgery
in which the average age of patients
receiving heart valves during the past
20 years has increased. As an example
from one of your references, Aupart
and colleagues5 reported a mean age
of 72.6 years in 2006. The same group
had published in 1996 on the same set
of patients with a mean age of 67.5
years.9 Suyker and Leicher1 also com-
ment on incompleteness in our table
showing long-term survival and dura-
bility outcomes (17–20 years) of
large-scale (n>1000 patients) studies
of bioprosthetic heart valves for aortic
valve replacement. We have never
claimed that this table is complete.
As pointed out in our article, it is
difficult to compare outcomes in
populations with differing baseline
characteristics, and different reports
rarely include all the same baseline
characteristics. With that as a back-The Journalground, the table only illustrates
a snapshot of the available data and
was reported as such.
Again, we thank them for their in-
terest in our publication.
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OUTCOME IN THE
TRANSECTION OF THE
PULMONARYARTERYAND
VEIN:
To the Editor:
We thank Dr Kamiyoshihara and
colleagues1 for bringing Dhaliwal and
colleagues’ study2 to our attention.
The content was both interesting and
clinically relevant. Understanding that
transection of the main pulmonary ar-
tery does not mandate continued resec-
tion is an invaluable piece of
information, but should only be used
when a patient is in extremis, warrant-
ing immediate transfer from the operat-
ing room.
We disagree with their conclusions
concerning vein ligation based on their
experience with a single case. Early
data suggest that ligation of both the
superior and inferior veins results in
death.3 However, other studies suggestry c Volume 141, Number 2 597
